Medeon Biodesign (ROCO:6499) Cyclically Adjusted FCF per Share: NT$-5.04 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6499 Medeon Biodesign Inc ROCO:6499
68 GF Score
Price NT$63.20
GF Value NT$107.56
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is Medeon Biodesign Cyclically Adjusted FCF per Share?

Medeon Biodesign ROCO:6499 68 Cyclically Adjusted FCF per Share is NT$-5.04 as of Dec. 2025. GuruFocus rates ROCO:6499 with a GF Score™ of 68/100 and a GF Value™ of NT$107.56 (Significantly Undervalued). The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Medeon Biodesign's adjusted free cash flow per share for the three months ended in Dec. 2025 was NT$-1.543. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is NT$-5.04 for the trailing ten years ended in Dec. 2025.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-07-27), Medeon Biodesign's current stock price is NT$63.20. Medeon Biodesign's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2025 was NT$-5.04. Medeon Biodesign's Cyclically Adjusted Price-to-FCF of today is .


Medeon Biodesign  (ROCO:6499) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Medeon Biodesign Cyclically Adjusted FCF per Share Related Terms


Medeon Biodesign Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Medeon Biodesign's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medeon Biodesign Cyclically Adjusted FCF per Share Chart

Medeon Biodesign Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -3.83 -4.54 -5.04

Medeon Biodesign Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.54 -4.77 -4.88 -4.99 -5.04

ROCO:6499 vs ISRG, BDX, MDLN: Cyclically Adjusted FCF per Share Comparison

For the Medical Instruments & Supplies subindustry, Medeon Biodesign's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medeon Biodesign Cyclically Adjusted Price-to-FCF vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Medeon Biodesign's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Medeon Biodesign's Cyclically Adjusted Price-to-FCF falls into.


ROCO:6499
68GF Score
Medeon Biodesign Inc ROCO:6499
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medeon Biodesign Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Medeon Biodesign's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2025 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=-1.543/324.0540*324.0540
=-1.543

Current CPI (Dec. 2025) = 324.0540.

Medeon Biodesign Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201603 -0.760 238.132 -1.034
201606 -0.716 241.018 -0.963
201609 -0.639 241.428 -0.858
201612 -0.638 241.432 -0.856
201703 -0.818 243.801 -1.087
201706 -1.286 244.955 -1.701
201709 -1.341 246.819 -1.761
201712 -2.364 246.524 -3.107
201803 5.755 249.554 7.473
201806 -0.769 251.989 -0.989
201809 -0.889 252.439 -1.141
201812 -0.719 251.233 -0.927
201903 -0.660 254.202 -0.841
201906 -0.715 256.143 -0.905
201909 -0.916 256.759 -1.156
201912 -0.879 256.974 -1.108
202003 -0.596 258.115 -0.748
202006 -0.479 257.797 -0.602
202009 -0.747 260.280 -0.930
202012 -0.042 260.474 -0.052
202103 -0.043 264.877 -0.053
202106 -0.745 271.696 -0.889
202109 -0.719 274.310 -0.849
202112 -1.731 278.802 -2.012
202203 0.210 287.504 0.237
202206 -2.844 296.311 -3.110
202209 -2.056 296.808 -2.245
202212 -1.576 296.797 -1.721
202303 -1.869 301.836 -2.007
202306 -2.671 305.109 -2.837
202309 -2.100 307.789 -2.211
202312 -2.089 306.746 -2.207
202403 -2.124 312.332 -2.204
202406 -3.106 314.175 -3.204
202409 -2.701 315.301 -2.776
202412 -1.900 315.605 -1.951
202503 -2.439 319.799 -2.471
202506 -1.463 322.561 -1.470
202509 -1.547 324.800 -1.543
202512 -1.543 324.054 -1.543

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of NT$-5.04 mean?
Medeon Biodesign (ROCO:6499) has a Cyclically Adjusted FCF per Share of NT$-5.04 as of Dec. 2025. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Medeon Biodesign and its competitors.
Is Medeon Biodesign's Cyclically Adjusted FCF per Share too high?
Medeon Biodesign's current Cyclically Adjusted FCF per Share is NT$-5.04. Overall, Medeon Biodesign has a GF Score™ of 68/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medeon Biodesign's Cyclically Adjusted FCF per Share compare to ISRG and BDX?
Medeon Biodesign's Cyclically Adjusted FCF per Share of NT$-5.04 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted FCF per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Medeon Biodesign and its competitors. Medeon Biodesign's current Cyclically Adjusted FCF per Share is NT$-5.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medeon Biodesign stock overvalued right now?
Based on GuruFocus' analysis, Medeon Biodesign (ROCO:6499) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$107.56, compared to a current price of NT$63.20 — trading 41.2% below its estimated fair value. The current Cyclically Adjusted FCF per Share is NT$-5.04. Medeon Biodesign's overall GF Score™ is 68/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Medeon Biodesign (ROCO:6499), the current Cyclically Adjusted FCF per Share is NT$-5.04 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medeon Biodesign (ROCO:6499) Overvalued in 2026?

Based on GuruFocus' analysis, Medeon Biodesign stock appears to be undervalued. The current stock price of NT$63.20 is trading 41.2% below its estimated GF Value™ of NT$107.56. GuruFocus considers Medeon Biodesign to be Significantly Undervalued.

Key valuation signals for ROCO:6499:

  • Cyclically Adjusted FCF per Share: NT$-5.04
  • GF Value™: NT$107.56 vs. price of NT$63.20 (41.2% below fair value)
  • GF Score™: 68/100 with 1 warning sign

No single metric tells the full story. See the ROCO:6499 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Medeon Biodesign Business Description

Address No. 116, HouGang Street, 7th Floor, Shilin District, Taipei, TWN, 11170
Medeon Biodesign Inc develops medical device products. The main services of the Group are the research and development of medical devices, manufacturing, and sale of injection molding and components of medical devices. The company provides products in the fields of cardiovascular and laparoscopic. Its business includes Medical Device Development Department and Medical Device Components Manufacturing and Sales Department. The majority of the company revenue comes from Medical Device Components Manufacturing and Sales Department segment. The company revenue is mainly derived from the USA.
68GF Score

Get the complete analysis for ROCO:6499

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$63.20
Price
NT$107.56
GF Value